Stentys SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Stentys SA Completes EUR 6 Million Capital Increase
Stentys SA announced the completion of its capital increase with preemptive rights launched on October 23, 2012. The final gross proceeds of the transaction amount to EUR 36,364,968 corresponding to the issuance of 3,030,414 new shares. Total subscription orders for this capital increase amounted to approximately EUR 47.6 million, i.e., a subscription rate of approximately 131.0%. 2,944,800 new shares were subscribed on an irreducible basis (“a titre irreductible”), representing approximately 97.2% of the new shares to be issued. Subscription orders subject to reduction (“a titre reductible”) amounted to 1,025,510 new shares and will, as a result, be satisfied only in part, i.e. for 85,614 new shares.
Latest Developments for Stentys SA
- Stentys SA Announces Positive Results of Its OPEN II study of Self-Apposing Stent
- Stentys SA Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than Conventional Drug-Eluting Stent
- Stentys SA Receives Approval to Expand CE Mark Indications of Its Self-Apposing Stent-DJ
- Stentys SA Announces Positive Interim Results of APPOSITION III Clinical Trial of STENTYS Self-Apposing Stents
- Share this
- Digg this